Drugs / PA5108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03604328 | Jul 2018 → Jun 2020 | open-angle glaucoma | PolyActiva Pty Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-10-30 | PolyActiva Pty Ltd | Results PolyActiva showcases repeat-dose clinical data out to 48 weeks polyactiva.com ↗
The trial met its efficacy and safety endpoints, representing a significant step forward in the company's vision to provide long-term, reliable drug delivery for glaucoma patients. |
| 2023-11-02 | PolyActiva Pty Ltd | Results PolyActiva reports promising Phase 2a clinical trial results polyactiva.com ↗
In the initial cohort, PA5108 showed a >20% reduction in intraocular pressure (IOP) at 12 weeks and 26 weeks. |
| 2022-03-17 | PolyActiva Pty Ltd | Results Positive Phase IIa results in glaucoma trial with low dose cohort polyactiva.com ↗ |
| 2022-03-17 | PolyActiva Pty Ltd | Results PolyActiva presents positive clinical trial results polyactiva.com ↗
The open-label, multicenter, Phase IIa study met both its primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort , demonstrating a potential significant benefit of the PA5108 Ocular Implant |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-30 | PolyActiva Pty Ltd | PolyActiva showcases repeat-dose clinical data out to 48 weeks polyactiva.com ↗ |
| 2023-11-02 | PolyActiva Pty Ltd | PolyActiva reports promising Phase 2a clinical trial results polyactiva.com ↗ |
| 2022-03-17 | PolyActiva Pty Ltd | Positive Phase IIa results in glaucoma trial with low dose cohort polyactiva.com ↗ |
| 2022-03-17 | PolyActiva Pty Ltd | PolyActiva presents positive clinical trial results polyactiva.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA5108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03604328 ↗ |
| Route | Other | “When Administered Intracamerally to the Anterior Chamber of the Eye” NCT03604328 ↗ |